source
- Biohaven secures up to $795 million partnership with SK Biopharma for global epilepsy drug rightsBiohaven announced a commercial partnership for its late-stage epilepsy program. South Korea-based SK Biopharma has agreed to pay up to $795 million for worldwide rights to the company's Kv7 ion ch…
- MassBio CEO warns 2025 may be biotech's toughest year amid China and NIH challengesMassachusetts is widely regarded as the epicenter of biotech because of its world‑class research institutions and vibrant startup ecosystem. MassBio CEO Kendalle Burlin O’Connell said 2025 will pr…